ESU Courses

The European School of Urology (ESU) organises two courses on Thursday 12 November, one on the medical treatment of metastatic renal cancer and the other on castrate resistant prostate cancer. Both courses draw high attendance and have limited space available. So those interested are advise to register on time. You can register for these ESU course when you register online for EMUC15. The ESU course will be added to your registration as an entitlement.

ESU course on Castrate resistant prostate cancer

Chair N. Mottet, Saint-Etienne (FR)

Max 100 participants

14.00 European School of Urology: a unique possibility for urological education N. Mottet, Saint-Etienne (FR)

14.05

Guidelines recommendations EAU, ESMO, NCCN on Prostate cancer

N. Mottet, Saint-Etienne (FR)

14.20

Second line hormonal manipulations in CRPC: role of enzalutamide and abiraterone

N. Mottet, Saint-Etienne (FR)

14.45 

Bone protective agents in CRPC, role of bisphosphonates and RANKL inhibitors

K. Fizazi, Villejuif (FR)

15.10

Break

15.30

Chemotherapeutic options in first and second line

S. Gillessen, St. Gallen (CH)

15.55

Role of vaccination, immunotherapy and radionuclides in CRPC

N. Mottet, Saint-Etienne (FR)

16.20

Interactive case discussion

K. Fizazi, Villejuif (FR)
S. Gillessen, St. Gallen (CH)
N. Mottet, Saint-Etienne (FR)

17.00

Close


​ESU course on Medical treatment of metastatic renal cancer

Chair J. Bellmunt, Boston (US)
Max 100 participants

14.00 European School of Urology: a unique possibility for urological education

M. Kuczyk, Hanover (DE)

14.05 Guidelines recommendations EAU, ESMO, NCCN on Renal cancer J. Bellmunt, Boston (US)
14.20 When to start with first - line treatment and is there a first choice agent? J. Bellmunt, Boston (US)
14.45 The role of cytoreductive nephrectomy in the era of targeted therapy M. Kuczyk, Hanover (DE)
15.10 Break
15.30 How to define the optimal sequential treatment after failure of first - line therapy? J. Bellmunt, Boston (US)
15.55 The efficacy of metastasectomy in metastatic renal cell cancer M. Kuczyk, Hanover (DE)
16.20 Interactive case discussion J. Bellmunt, Boston (US) & M. Kuczyk, Hanover (DE)
17.00 Close

Registration fee excluding 21% VAT

members* €50.00
non-members €75.00

* Discounted fee applicable for members of the ESMO, ESTRO and EAU.